Dr. Parekkadan will discuss Engineered Cell Therapeutics at the conference in NJ. His talk will be on Saturday, May 20th at 4pm.
Delivering on the promise of cell therapy
Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel approaches to cell therapy.
Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.